Quick verdict
Hims & Hers is the better pick for most patients on overall scoring. Same-day prescription, no lock-in, and brand-name confidence. The famous $199 compounded era ended in March 2026 after the Novo Nordisk settlement; new patients now route to branded products only.
That said, Found wins on specific dimensions. Found has the broadest medication catalog of any program here, including off-label tirzepatide and orforglipron access through their Foundayo program. The 6-month non-refundable subscription is the catch.
Side-by-side
| Hims & Hers | Found | |
|---|---|---|
| Starts from | $199/mo (incl. medication) | $99/mo (+ med separate) |
| Lock-in | Month-to-month | 6-month lock-in |
| Time to prescription | 1 day | 5 days |
| Consultation type | Asynchronous | Asynchronous |
| Affiliate network | Impact | Impact |
Score by dimension
Five dimensions, ten points each. The winner of each dimension is highlighted.
| Hims & Hers | Found | |
|---|---|---|
| Pricing transparency | 7/10 | 6/10 |
| Cancellation terms | 9/10 | 3/10 |
| Onboarding experience | 9/10 | 8/10 |
| Medication options | 7/10 | 9/10 |
| Member outcomes | 5/10 | 5/10 |
When to choose Hims & Hers
Patients who want a fast, low-friction async path to a branded GLP-1 prescription with predictable all-in monthly pricing.
When to choose Found
Patients whose obesity medicine clinician has flagged a non-standard medication path (multiple drug classes, off-label combinations, or 503A-compounded options that other programs have exited).
FAQ
Is Hims & Hers cheaper than Found?
Can I switch from Hims & Hers to Found mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart →